Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...

Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development Genialis, the RNA biomarker company, today announced an ...

"Our study is the largest study to date that has attempted to detect how these small molecules in the blood may serve as biomarkers for SIDS," said researcher Keith L. Keene, Ph.D., founding director ...

The challenges encountered by proteomic researchers seeking diagnostic, prognostic and mechanistic markers were the subject of the 1-day meeting, Proteomics: Advances in Biomarker Discovery hosted ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

During the past two decades, cancer biomarker discovery has been boosted by the advent of new technologies for high-throughput molecular profiling, such as microarray analysis and mass spectrometry.

PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to ...

More information: Andrew Kalra et al, Discovery of Methylated DNA Biomarkers for Potential Non-Endoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma, American Journal of ...

Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a ...